AN2 Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
AN2 Therapeutics, Inc. (ANTX) reported Basic Shares Outstanding (Weighted Average) of 44.76 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- AN2 Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 44.76M shares, a 48.35% increase year-over-year.
- AN2 Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 34.06M shares, a 13.33% increase year-over-year.
- AN2 Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 30.36M shares, a 1.59% increase year-over-year.
- AN2 Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 30.28M shares, a 1.46% increase year-over-year.
- AN2 Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 30.22M shares, a 1.30% increase from fiscal 2024.
- AN2 Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 29.83M shares, a 26.39% increase from fiscal 2023.
- AN2 Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 23.60M shares, a 53.85% increase from fiscal 2022.
- AN2 Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 15.34M shares, a 481.46% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 44.76M shares 10-Q · filed 2026-08-11 | 39.44M shares 10-Q · filed 2026-08-11 | 36.39M shares derived: average of 3 quarters · filed 2026-08-11 | 34.86M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 34.06M shares 10-Q · filed 2026-05-11 | 32.21M shares derived: average of 2 quarters · filed 2026-05-11 | 31.56M shares derived: average of 3 quarters · filed 2026-05-11 | 31.22M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 30.36M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 30.32M shares derived: average of 2 quarters · filed 2026-03-17 | 30.27M shares derived: average of 3 quarters · filed 2026-08-11 | 30.22M shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 30.28M shares 10-Q · filed 2025-11-12 | 30.22M shares derived: average of 2 quarters · filed 2026-08-11 | 30.17M shares 10-Q · filed 2025-11-12 | 30.10M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 30.17M shares 10-Q · filed 2026-08-11 | 30.11M shares 10-Q · filed 2026-08-11 | 30.04M shares derived: average of 3 quarters · filed 2026-08-11 | 29.99M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 30.05M shares 10-Q · filed 2026-05-11 | 29.97M shares derived: average of 2 quarters · filed 2026-05-11 | 29.93M shares derived: average of 3 quarters · filed 2026-05-11 | 29.90M shares derived: average of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | 29.88M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 29.86M shares derived: average of 2 quarters · filed 2026-03-17 | 29.85M shares derived: average of 3 quarters · filed 2026-03-17 | 29.83M shares 10-K · filed 2026-03-17 |
| 2024-09-30 | 29.84M shares 10-Q · filed 2025-11-12 | 29.83M shares derived: average of 2 quarters · filed 2025-11-12 | 29.81M shares 10-Q · filed 2025-11-12 | 29.81M shares derived: average of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | 29.82M shares 10-Q · filed 2025-08-12 | 29.79M shares 10-Q · filed 2025-08-12 | 29.80M shares derived: average of 3 quarters · filed 2025-08-12 | 28.76M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 29.76M shares 10-Q · filed 2025-05-13 | 29.78M shares derived: average of 2 quarters · filed 2025-05-13 | 28.40M shares derived: average of 3 quarters · filed 2025-05-13 | 26.18M shares derived: average of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | 29.80M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | 27.72M shares derived: average of 2 quarters · filed 2025-03-25 | 24.98M shares derived: average of 3 quarters · filed 2025-03-25 | 23.60M shares 10-K · filed 2025-03-25 |
| 2023-09-30 | 25.65M shares 10-Q · filed 2024-11-13 | 22.57M shares derived: average of 2 quarters · filed 2024-11-13 | 21.53M shares 10-Q · filed 2024-11-13 | 20.98M shares derived: average of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | 19.50M shares 10-Q · filed 2024-08-13 | 19.44M shares 10-Q · filed 2024-08-13 | 19.43M shares derived: average of 3 quarters · filed 2024-08-13 | 19.41M shares derived: average of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | 19.39M shares 10-Q · filed 2024-05-14 | 19.39M shares derived: average of 2 quarters · filed 2024-05-14 | 19.38M shares derived: average of 3 quarters · filed 2024-05-14 | 19.35M shares derived: average of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | 19.40M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 19.37M shares derived: average of 2 quarters · filed 2024-03-29 | 19.33M shares derived: average of 3 quarters · filed 2024-03-29 | 15.34M shares 10-K · filed 2024-03-29 |
| 2022-09-30 | 19.35M shares 10-Q · filed 2023-11-09 | 19.30M shares derived: average of 2 quarters · filed 2023-11-09 | 13.99M shares 10-Q · filed 2023-11-09 | 11.11M shares derived: average of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | 19.26M shares 10-Q · filed 2023-08-10 | 11.26M shares 10-Q · filed 2023-08-10 | 8.36M shares derived: average of 3 quarters · filed 2023-08-10 | 6.93M shares derived: average of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | 3.18M shares 10-Q · filed 2023-05-11 | 2.92M shares derived: average of 2 quarters · filed 2023-05-11 | 2.83M shares derived: average of 3 quarters · filed 2023-05-11 | 2.78M shares derived: average of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | 2.65M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | 2.65M shares derived: average of 2 quarters · filed 2023-03-29 | 2.64M shares derived: average of 3 quarters · filed 2023-03-29 | 2.64M shares 10-K · filed 2023-03-29 |
| 2021-09-30 | 2.64M shares 10-Q · filed 2022-11-09 | 2.64M shares derived: average of 2 quarters · filed 2022-11-09 | 2.63M shares 10-Q · filed 2022-11-09 | |
| 2021-06-30 | 2.63M shares 10-Q · filed 2022-08-11 | 2.63M shares 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |